These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 12592330

  • 1. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
    Byrd JC, Peterson B, Piro L, Saven A, Vardiman JW, Larson RA, Schiffer C.
    Leukemia; 2003 Feb; 17(2):323-7. PubMed ID: 12592330
    [Abstract] [Full Text] [Related]

  • 2. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.
    Byrd JC, Peterson BL, Gabrilove J, Odenike OM, Grever MR, Rai K, Larson RA, Cancer and Leukemia Group B.
    Clin Cancer Res; 2005 Jun 01; 11(11):4176-81. PubMed ID: 15930354
    [Abstract] [Full Text] [Related]

  • 3. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
    Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA.
    N Engl J Med; 2000 Dec 14; 343(24):1750-7. PubMed ID: 11114313
    [Abstract] [Full Text] [Related]

  • 4. Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study.
    Martell RE, Peterson BL, Cohen HJ, Petros WP, Rai KR, Morrison VA, Elias L, Shepherd L, Hines J, Larson RA, Schiffer CA, Hurwitz HI.
    Cancer Chemother Pharmacol; 2002 Jul 14; 50(1):37-45. PubMed ID: 12111110
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Fludarabine treatment in B-cell chronic lymphocytic leukemia: response, toxicity and survival analysis in 47 cases.
    Stelitano C, Morabito F, Kropp MG, Callea V, Iuliano F, Oriana V, Levato D, Nobile F, Molica S, Brugiatelli M.
    Haematologica; 1999 Apr 14; 84(4):317-23. PubMed ID: 10190945
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia.
    Frankel AE, Fleming DR, Hall PD, Powell BL, Black JH, Leftwich C, Gartenhaus R.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 1):3555-61. PubMed ID: 14506141
    [Abstract] [Full Text] [Related]

  • 11. Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia.
    Robak T, Smolewski P, Cebula B, Grzybowska-Izydorczyk O, Błoński JZ.
    Eur J Haematol; 2007 Aug 01; 79(2):107-13. PubMed ID: 17635235
    [Abstract] [Full Text] [Related]

  • 12. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
    Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD, Böttcher S, Staib P, Kiehl M, Eckart MJ, Kranz G, Goede V, Elter T, Bühler A, Winkler D, Kneba M, Döhner H, Eichhorst BF, Hallek M, Wendtner CM.
    J Clin Oncol; 2011 Sep 10; 29(26):3559-66. PubMed ID: 21844497
    [Abstract] [Full Text] [Related]

  • 13. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
    O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, Chanan-Khan AA, Seymour JF, Bociek RG, Pavletic S, Rai KR.
    J Clin Oncol; 2007 Mar 20; 25(9):1114-20. PubMed ID: 17296974
    [Abstract] [Full Text] [Related]

  • 14. Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia.
    Robak T, Błasinka-Morawiec M, Krykowski E, Kasznicki M, Płuzanska A, Potemski P, Hellmann A, Zaucha JM, Lewandowski K, Dmoszynska A, Hansz J, Komarnicki M, Konopka L, Durzynski T, Ceglarek B, Sikorska A, Kotlarek-Haus S, Mazur G, Urasinski I, Zdziarska B, Maj S, Kopec I, Skotnicki AB, Dwilewicz-Trojaczek J, Grieb P.
    Leuk Lymphoma; 1996 Aug 20; 22(5-6):509-14. PubMed ID: 8882965
    [Abstract] [Full Text] [Related]

  • 15. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population.
    Perkins JG, Flynn JM, Howard RS, Byrd JC.
    Cancer; 2002 Apr 01; 94(7):2033-9. PubMed ID: 11932906
    [Abstract] [Full Text] [Related]

  • 16. [Treatment with fludarabine of chronic refractory lymphoid leukemia].
    Herrero M, Cabrera JR, Briz M, Forés R, Díez JL, Regidor C, Sanjuán I, Fernández MN.
    Sangre (Barc); 1995 Apr 01; 40(2):115-9. PubMed ID: 7784940
    [Abstract] [Full Text] [Related]

  • 17. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Faderl S, Rai K, Gribben J, Byrd JC, Flinn IW, O'Brien S, Sheng S, Esseltine DL, Keating MJ.
    Cancer; 2006 Sep 01; 107(5):916-24. PubMed ID: 16832816
    [Abstract] [Full Text] [Related]

  • 18. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
    Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, Verstovsek S, Ferrajoli A, Wierda W, Alvarado Y, O'Brien SM, Albitar M, Keating MJ, Giles FJ.
    Cancer; 2003 Apr 01; 97(7):1711-20. PubMed ID: 12655528
    [Abstract] [Full Text] [Related]

  • 19. A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia.
    Robertson LE, O'Brien S, Kantarjian H, Koller C, Beran M, Andreeff M, Lerner S, Plunkett W, Keating MJ.
    Leukemia; 1995 Sep 01; 9(9):1444-9. PubMed ID: 7658710
    [Abstract] [Full Text] [Related]

  • 20. [Long-term results with fludarabine monotherapy in chronic lymphocytic leukemia].
    Varga F, Lehoczky D, Demeter J.
    Orv Hetil; 1999 Aug 01; 140(31):1731-5. PubMed ID: 10463032
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.